JAK1 and JAK2 modulate the transduction signal after IFN-γ binds to its receptor [102], and as such, the downstream IFN-γ/CXCL10 signaling pathway may be a potential therapeutic target in vitiligo. The gene discussed is CXCL10; the disease is vitiligo.